Pathway to Cures Invests in SeraGene Therapeutics to Advance RNA/LNP Therapies for Bleeding Disorders

NEW YORK – November 24, 2025– Pathway to Cures (P2C), the venture philanthropy fund of the National Bleeding Disorders Foundation (NBDF), today announced a strategic investment in SeraGene Therapeutics, a pioneering biotechnology company developing transformative RNA-based and nanomedicine therapies for blood coagulation disorders.

The investment is part of a funding round that saw P2C join Hextwo Capital as an early investor in SeraGene. This commitment is aimed at accelerating the development of novel treatments with the potential to significantly improve the lives of individuals in the bleeding disorders community, particularly women.

LNP Technology Targets Coagulation and Women’s Health

SeraGene Therapeutics, which originated from the Versiti Blood Research Institute in Wisconsin, USA, and the Center for Blood Research at the University of British Columbia (UBC) in Canada, has quickly gained recognition for its innovative platform.

SeraGene’s proprietary technology utilizes advanced lipid nanoparticles (LNPs) to deliver RNA directly to liver cells. This approach offers enhanced treatment precision and reduces the need for frequent dosing compared to traditional therapies. The company’s focus is twofold:

1. Clot Stabilization: Precisely suppressing plasminogen to stabilize a blood clot.

2. Gene Enhancement: Enhancing the expression of specific genes required for coagulation.

“The potential for SeraGene’s innovative therapies to improve lives in our bleeding disorders community, especially for women and girls, makes this an exciting partnership for us,” said Teri Willey, Managing Director of NBDF’s Pathway to Cures venture fund. “We are delighted to expand our portfolio with this strategic investment and impact the treatment of bleeding disorders including von Willebrand disease (VMD) with a focus on women’s health.”

SeraGene, based in Vancouver, has been recognized as an emerging innovator, having been named a “Company to Watch” at the Life Sciences BC Awards and a finalist for the prestigious Eli Lilly Grand Challenge in 2025.

NBDF’s Fund Strategy

Pathway to Cures (P2C) was established by the NBDF to accelerate the development of cures across all inheritable blood and bleeding disorders. P2C invests in innovative therapies and technologies and subsequently reinvests the proceeds back into the fund to amplify its impact and support promising biotech companies.